Medscape InDiscussion: Bladder Cancer

Dr Cheryl Lee and Diane Zipursky Quale, Co-founder and Director of the Bladder Cancer Advocacy Network, discuss successes and ongoing efforts to level the playing field for those who experience bladder cancer.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/987109). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Bladder Cancer Advisory Network https://bcan.org/

Bladder Cancer Awareness Month 2023 https://bcan.org/bladder-cancer-awareness-month-2023/

Bladder Cancer Matters Podcast https://bcan.org/bladder-cancer-podcast/

BCAN Survivor to Survivor https://bcan.org/find-support/survivor-to-survivor/

Bladder Cancer Young Investigator Awards https://bcan.org/young-investigator-awards/

American Urological Association https://www.auanet.org/

Department of Defense Appropriations for Fiscal Year 2023 https://www.congress.gov/event/118th-congress/senate-event/LC70188/text?s=1&r=3

Bladder Cancer and Veterans: What You Need to Know https://news.va.gov/103200/bladder-cancer-and-veterans-what-you-need-to-know/#:~:text=Exposure%20risks%20for%20Veterans%3A%20Agent,chemicals%20during%20their%20military%20service.

Drs Cheryl Lee and Shekinah Elmore talk about how stereotactic body radiation therapy (SBRT) is being used in the treatment of oligometastatic bladder cancer — and how it's making a difference in patients' lives.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/987108). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

ESTRO ACROP Guidelines for External Beam Radiotherapy of Patients With Uncomplicated Bone Metastases https://www.estro.org/About/Newsroom/Newsletter/Read-it-before-your-patients/ESTRO-ACROP-guidelines-for-external-beam-radio-(1)

Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic (1-3 Metastases) Cancer (SABR-COMET-3) https://clinicaltrials.gov/ct2/show/NCT03862911

IMRT https://www.cancer.gov/publications/dictionaries/cancer-terms/def/imrt

Metastasis-directed Radiation Therapy With Consolidative Intent for Oligometastatic Urothelial Carcinoma: A Systematic Review and Meta-analysis https://pubmed.ncbi.nlm.nih.gov/35625979/

Trimodality Therapy for Bladder Cancer: Modern Management and Future Directions https://pubmed.ncbi.nlm.nih.gov/30855374/

Drs Cheryl Lee and Andrea Apolo discuss combination systemic therapy strategies for urothelial carcinoma, including dose de-escalation for toxicity reduction, and how ctDNA efforts are paving the way for precision medicine with the promise of biomarkers.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/987107). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Systemic Treatment for Advanced Urothelial Cancer: An Update on Recent Clinical Trials and Current Treatment Options https://pubmed.ncbi.nlm.nih.gov/32668516/

PD-L1 Assessment in Urothelial Carcinoma: A Practical Approach https://pubmed.ncbi.nlm.nih.gov/31930091/

Immune Checkpoint Inhibitors in Cancer Therapy https://pubmed.ncbi.nlm.nih.gov/35621637/

FGFR3 Alterations in the Era of Immunotherapy for Urothelial Bladder Cancer https://pubmed.ncbi.nlm.nih.gov/33224141/

BCG-Unresponsive High-Grade Non-muscle Invasive Bladder Cancer: What Does the Practicing Urologist Need to Know? https://pubmed.ncbi.nlm.nih.gov/33772322/

Drs Cheryl Lee and Tom Powles talk about ctDNA and personalized medicine approaches for advanced bladder cancer as we sit at the precipice of change.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/987106). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Circulating Tumor DNA: A Promising Biomarker in the Liquid Biopsy of Cancer https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217053/

A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy (IMvigor011) https://clinicaltrials.gov/ct2/show/NCT04660344

A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection (IMvigor010) https://clinicaltrials.gov/ct2/show/NCT02450331

Drs Cheryl Lee and Karim Chamie talk about efforts to develop nogapendekin alfa, aka N-803, and where it may fit into the shifting treatment paradigm for non-muscle invasive bladder cancer.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/987105). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

BCG-Unresponsive High-Grade Non-Muscle-Invasive Bladder Cancer: What Does the Practicing Urologist Need to Know? https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7997797/

Final Clinical Results of Pivotal Trial of IL-15rαfc Superagonist N-803 With BCG in BCG-Unresponsive CIS and Papillary Non-Muscle-Invasive Bladder Cancer (NMIBC) https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.4508

PK Sub-Study of QUILT-3.032 (CA ALT-803-01-16) and of QUILT-2.005 (CA ALT-803-01-14) https://www.clincosm.com/trial/pk-sub-quilt-3032-ca-alt-803-01-16-2005-14

Drs Cheryl Lee and Stephen Boorjian share detailed insights about a model drug development partnership involving the first-in-class therapy for BCG-unresponsive non–muscle-invasive bladder cancer.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/987104). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Diagnosis and Treatment of Non-muscle Invasive Bladder Cancer: AUA/SUO Guideline (2020) https://www.auanet.org/guidelines-and-quality/guidelines/bladder-cancer-non-muscle-invasive-guideline

ADSTILADRIN (=INSTILADRIN) in Patients With High Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC) https://clinicaltrials.gov/ct2/show/NCT02773849

Intravesical Nadofaragene Firadenovec Gene Therapy for BCG-unresponsive Non-muscle-invasive Bladder Cancer: A Single-arm, Open-label, Repeat-dose Clinical Trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7988888/

Drs Cheryl Lee and Sima Porten discuss urinary biomarkers, enhanced cystoscopy, treatments on the horizon, and communication with team members from the cytopathology lab using the PARIS classification.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/970416). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Paris System for Reporting Urinary Cytopathology https://paris.soc.wisc.edu/index.htm

Bladder Cancer Biomarkers: Optimal Utilization for Diagnosis and Recurrence https://www.urotoday.com/recent-abstracts/urologic-oncology/bladder-cancer/93133-bladder-cancer-biomarkers-optimal-utilization-for-diagnosis-and-recurrence-everyday-urology-full-text-article.html

Diagnostic Performance of Oncuria™, a Urinalysis Test for Bladder Cancer https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8025333/

Immunological Hallmarks for Clinical Response to BCG in Bladder Cancer https://www.frontiersin.org/articles/10.3389/fimmu.2020.615091/full

Drs Cheryl Lee and Angela Smith discuss bladder cancer research focused on disparities in healthcare affecting women and minorities.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/970415). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Bladder Cancer https://www.medscape.com/resource/bladder-cancer

Racial Disparity in Bladder Cancer: Trends in Tumor Presentation at Diagnosis https://www.auajournals.org/doi/10.1016/j.juro.2006.04.074

Sex and Racial Disparities in the Treatment and Outcomes of Muscle-Invasive Bladder Cancer https://linkinghub.elsevier.com/retrieve/pii/S0090-4295(20)30992-4

Drs Cheryl Lee and Sophia Kamran discuss the exciting and evolving role of radiation therapy in treating bladder cancer.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/970414). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Trimodality Therapy for Bladder Cancer: Modern Management and Future Directions https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7440298/

Adaptive Radiation Therapy for Bladder Cancer: A Review of Adaptive Techniques Used in Clinical Practice https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4968556/

Clinical Implementation of Artificial Intelligence-Driven Cone-Beam Computed Tomography-Guided Online Adaptive Radiotherapy in the Pelvic Region https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8057957/

Drs Cheryl Lee and Peter Black share exciting new ways to use liquid biopsy ctDNA testing for bladder cancer diagnostics and patient monitoring.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/970413). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Adjuvant Atezolizumab Versus Observation in Muscle-Invasive Urothelial Carcinoma (Imvigor010): A Multicentre, Open-Label, Randomised, Phase 3 Trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8495594/

ctDNA Guiding Adjuvant Immunotherapy in Urothelial Carcinoma https://www.nature.com/articles/s41586-021-03642-9

ClinicalTrials.gov: Treatment of Metastatic Bladder Cancer at the Time of Biochemical reLApse Following Radical Cystectomy (TOMBOLA) https://clinicaltrials.gov/ct2/show/NCT04138628